

**Title:** Balancing the Charge, Electrolyte Imbalances After Solid Organ Transplant

**Presenter:**

Ghaleb Ismail, PharmD  
PGY2 Pharmacy Resident - Solid Organ Transplant  
UPMC Presbyterian

Date: 10/30/2024

**Learning Objectives:**

1. Discuss the pathophysiology of electrolyte imbalances in solid organ transplant (SOT) recipients
2. Describe the clinical manifestations of electrolyte imbalances in SOT recipients
3. Identify the treatment strategies for electrolyte imbalances in SOT recipients

**Abstract:**

Electrolyte imbalances are a frequent complication in solid organ transplant (SOT) recipients, largely due to the effects of immunosuppressive therapy, altered renal function, and surgical stress. Medications such as calcineurin inhibitors (e.g., tacrolimus, cyclosporine), corticosteroids, and diuretics are known to disrupt normal electrolyte regulation, leading to imbalances like hyperkalemia, hypomagnesemia, and metabolic acidosis. Additionally, changes in kidney function after transplantation can further exacerbate these disturbances by impairing the body's ability to maintain proper electrolyte and fluid balance. Clinically, electrolyte imbalances can present with a wide range of symptoms, depending on the specific electrolyte involved, posing a significant risk if not addressed promptly. Early detection and intervention are critical to managing these imbalances effectively and preventing serious complications. Treatment strategies for electrolyte imbalances in SOT recipients are tailored to the type and severity of the disturbance. Management typically involves a combination of electrolyte replacement, adjustment of immunosuppressive medications, and in some cases, the use of adjunct therapies. While existing strategies are effective for managing electrolyte imbalances in SOT recipients, challenges remain in optimizing treatment, especially given the complex relationship between medications and renal function in SOT patients. Further research is needed to establish more comprehensive guidelines for preventing and treating these imbalances, with an emphasis on individualized approaches based on the type of transplant, immunosuppressive regimen, and renal function.

**References:**

1. Tobias A, Ballard BD, Mohiuddin SS. Physiology, Water Balance. In: StatPearls. Treasure Island (FL): StatPearls Publishing; October 3, 2022.
2. Brinkman JE, Dorius B, Sharma S. Physiology, Body Fluids. In: StatPearls. Treasure Island (FL): StatPearls Publishing; January 27, 2023.
3. Electrolyte Homeostasis. In: Wells BG, DiPiro JT, Schwinghammer TL, DiPiro CV. eds. Pharmacotherapy Quick Guide. McGraw-Hill Education; 2017. Accessed September 26, 2024. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=2177&sectionid=165474611>
4. Jones KM, Neill KK, Warmack T. Chapter 34. Electrolyte Disorders. In: Sutton S. eds. McGraw-Hill's NAPLEX® Review Guide. The McGraw-Hill Companies; 2011. Accessed October 02, 2024. <https://accesspharmacy.mhmedical.com/content.aspx?bookid=458&sectionid=41034071>
5. Pochineni V, Rondon-Berrios H. Electrolyte and Acid-Base Disorders in the Renal Transplant Recipient. *Front Med (Lausanne)*. 2018;5:261. Published 2018 Oct 2. doi:10.3389/fmed.2018.00261
6. Nogueira de Sa P, Narayanan M, Lim MAC. Electrolyte and Acid-Base Abnormalities After Kidney Transplantation. *Adv Kidney Dis Health*. 2024;31(5):450-457. doi:10.1053/j.akdh.2024.03.007
7. Miles CD, Westphal SG. Electrolyte Disorders in Kidney Transplantation. *Clin J Am Soc Nephrol*. 2020;15(3):412-414. doi:10.2215/CJN.09470819

8. Rizk JG, Lazo JG Jr, Quan D, et al. Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. *Rev Endocr Metab Disord*. 2021;22(4):1157-1170. doi:10.1007/s11154-021-09677-7
9. Almalki B, Cunningham K, Kapugi M, Kane C, Agrawal A. Management of hyperkalemia: A focus on kidney transplant recipients. *Transplant Rev (Orlando)*. 2021;35(2):100611. doi:10.1016/j.trre.2021.100611
10. Shockey W, Wiegel JJ, Parajuli S, Garg N, Swanson KJ, Mandelbrot DA. Potassium-lowering effects of sodium zirconium cyclosilicate in the early post-transplant period. *Clin Transplant*. 2024;38(1)
11. . doi:10.1111/ctr.15156
12. Abigail M S, Eric D L, Scott G W, Clifford D M. Safety and efficacy of patiromer in kidney and liver transplant recipients. *J Clin Nephrol Ren Care*. 2022;8(1).
13. Gheith OA, Dahab M, Nagib AM, et al. Fludrocortisone Among Adult Renal Transplant Recipients With Persistent Hyperkalemia: Single-Center Experience. *Exp Clin Transplant*. 2022;20(Suppl 1):69-73. doi:10.6002/ect.MESOT2021.O27
14. Garnier AS, Duveau A, Planchais M, Subra JF, Sayegh J, Augusto JF. Serum Magnesium after Kidney Transplantation: A Systematic Review. *Nutrients*. 2018;10(6):729. Published 2018 Jun 6. doi:10.3390/nu10060729
15. Hod T, Isakov O, Patibandla BK, et al. Posttransplantation Hypomagnesemia as a Predictor of Better Graft Function after Transplantation. *Kidney Blood Press Res*. 2020;45(6):982-995. doi:10.1159/000510797
16. Isakov O, Patibandla BK, Christopher KB, Chandraker A, Hod T. Impact of Post-Transplantation Hypomagnesemia on Long-Term Graft and Patient Survival after Transplantation. *Kidney Blood Press Res*. 2022;47(5):341-353. doi:10.1159/000522233
17. Musso CG, Castañeda A, Giordani M, et al. Hyponatremia in kidney transplant patients: its pathophysiologic mechanisms. *Clin Kidney J*. 2018;11(4):581-585. doi:10.1093/ckj/sfy016
18. Berchtold L, Filzer A, Achermann R, et al. Impact of Hyponatremia after Renal Transplantation on Decline of Renal Function, Graft Loss and Patient Survival: A Prospective Cohort Study. *Nutrients*. 2021;13(9):2995. Published 2021 Aug 27. doi:10.3390/nu13092995
19. Han SS, Han M, Park JY, et al. Posttransplant Hyponatremia Predicts Graft Failure and Mortality in Kidney Transplantation Recipients: A Multicenter Cohort Study in Korea. *PLoS One*. 2016;11(5)
20. . Published 2016 May 23. doi:10.1371/journal.pone.0156050
21. Lee J, Kim DK, Lee JW, et al. Rapid correction rate of hyponatremia as an independent risk factor for neurological complication following liver transplantation. *Tohoku J Exp Med*. 2013;229(2):97-105. doi:10.1620/tjem.229.97
22. Schulte K, Püchel J, Schüssel K, Borzikowsky C, Kunzendorf U, Feldkamp T. Effect of Sodium Bicarbonate in Kidney Transplant Recipients With Chronic Metabolic Acidosis. *Transplant Direct*. 2019;5(7)
23. . Published 2019 Jun 27. doi:10.1097/TXD.0000000000000910
24. Bohling R, Grafals M, Moreau K, et al. A Pilot Study of the Safety and Efficacy of Alkali Therapy on Vascular Function in Kidney Transplant Recipients. *Kidney Int Rep*. 2021;6(9):2323-2330. Published 2021 Jun 24. doi:10.1016/j.ekir.2021.06.006
25. Mohebbi N, Ritter A, Wiegand A, et al. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial. *Lancet*. 2023;401(10376):557-567. doi:10.1016/S0140-6736(22)02606-X
26. Bartolomeo K, Tan XY, Fatica R. Extraosseous calcification in kidney disease [published correction appears in *Cleve Clin J Med*. 2022 Apr 1;89(4):223.]. *Cleve Clin J Med*. 2022;89(2):81-90. Published 2022 Feb 1. doi:10.3949/ccjm.89a.21073
27. Delos Santos R, Rossi A, Coyne D, Maw TT. Management of Post-transplant Hyperparathyroidism and Bone Disease. *Drugs*. 2019 Apr;79(5):501-513. doi:10.1007/s40265-019-01074-4. PMID: 30811012; PMCID: PMC6439149.
28. Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, Rutkowski B, Schaefer H, Deng H, Torregrosa JV, Wuthrich RP, Yue S. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. *Am J Transplant*. 2014 Nov;14(11):2545-55. doi:10.1111/ajt.12911. Epub 2014 Sep 15. PMID: 25225081.
29. Phosphate supplements. *GlobalRPH*.

**Audience Response Questions:**

- 1. Which of the following is the most appropriate management strategy for Mr. Smith?**
  - A) Reduce the dose of tacrolimus
  - B) Administer loop diuretics
  - C) Implement a potassium-restricted diet
  - D) Use potassium binders such as sodium polystyrene sulfonate or Patiromer
  
- 2. What is the primary mechanism leading to hypomagnesemia in solid organ transplant (SOT) recipients?**
  - A) Decreased dietary intake
  - B) Kidney wasting of magnesium due to calcineurin inhibitors
  - C) Increased gastrointestinal losses
  - D) Hypoparathyroidism
  
- 3. Which electrolyte imbalance can contribute to the development of metabolic acidosis in post-kidney transplant patients?**
  - A) Hypercalcemia
  - B) Hyperkalemia
  - C) Hypermagnesemia
  - D) Hypophosphatemia
  
- 4. Which of the following phosphorus supplements would be most appropriate for Mr. Smith?**
  - A) Neutra-Phos®
  - B) Neutra-Phos K®
  - C) K-Phos® Neutral
  - D) Fleet® Phospho Soda